# 60th Medical Group (AMC), Travis AFB, CA

## INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC)

### **FINAL REPORT SUMMARY**

(Please type all information. Use additional pages if necessary.)

DATE: 1 March 2018

FPARTI	MENT: SGDDS			PHON	JF #· 707-4	123-7085		
			7	PHONE #: 707-423-7085  LAST TRIENNIAL REVISION DATE: N/A				
		<b>FE:</b> 23 March 2017	1					
UNDING	S SOURCE: SG							
. <u>R</u>	ECORD OF AN	IMAL USAGE:						
Ani	mal Species:	Total # Ap	proved	# Used	this FY	Total # Used to Date		
Rattus ı	norvegicus	180	0	0		0		
_	DOTO 001 TV	NE / OU 4 D 4 OTED!	OTIOS (OI					
	PROTOCOL TYPE / CHARACTERISTICS: (Check all applicable terms in EACH column)							
-					Prolonged Restraint			
_	Training: no	Health	Promotion	-	Multiple Survival Surgery			
_	Research: Survival (chronic) Pre			vention Behavioral Study				
_	Research: non-Survival (acute) Ut			tion Mgt.	_	Adjuvant Use		
_	Other (	)	Other	(Treatment	) _	Biohazard		
Р	ROTOCOL PAI	N CATEGORY (US	SDA): (Check a	applicable)	С	X D E		
			`	,				
<u>P</u>	PROTOCOL STATUS:  *Request Protocol Closure:							
	Inactive, protocol never initiated  _X_ Inactive, protocol initiated but has not/will not be completed							
		•			•			
		pleted, all approved	d procedures/a	nimal uses h	ave been o	completed		
	Previous Amendments: List all amendments made to the protocol. IF none occurred, state NONE. Do not use N/A.							
LI	ist all amenume	ns made to the pro	nocoi. I <b>r none</b>	occurrea, s	siale NUN	E. DO HOL USE N/A.		
<u>F</u>		udy Chronologica		the Ohen :				
	Amendment	Date of	Summary of	tne Change				
	Number	Approval						

PROTOCOL #: FDG20170016A

**6. FUNDING STATUS:** Funding allocated: \$9,240 Funds remaining: \$9,240

7.	PROTOCOL	PERSONNEL	<b>CHANGES:</b>
----	----------	-----------	-----------------

Have there been any personnel/staffing changes (PI/CI/AI/TC/Instructor) since the last IACUC approval of protocol, or annual review?

\_\_\_\_ Yes \_\_\_X\_No

If yes, complete the following sections (Additions/Deletions). For additions, indicate whether or not the IACUC has approved this addition.

ADDITIONS: (Include Name, Protocol function - PI/CI/AI/TC/Instructor, IACUC approval - Yes/No)

DELETIONS: (Include Name, Protocol function - PI/CI/AI/TC/Instructor, Effective date of deletion)

**8.** PROBLEMS / ADVERSE EVENTS: Identify any problems or adverse events that have affected study progress. Itemize adverse events that have led to unanticipated animal illness, distress, injury, or death; and indicate whether or not these events were reported to the IACUC.

None

### 9. REDUCTION, REFINEMENT, OR REPLACEMENT OF ANIMAL USE:

**REPLACEMENT (ALTERNATIVES):** Since the last IACUC approval, have alternatives to animal use become available that could be substituted in this protocol without adversely affecting study or training objectives?

No

**REFINEMENT:** Since the last IACUC approval, have any study refinements been implemented to reduce the degree of pain or distress experienced by study animals, or have animals of lower phylogenetic status or sentience been identified as potential study/training models in this protocol?

No

**REDUCTION:** Since the last IACUC approval, have any methods been identified to reduce the number of live animals used in this protocol?

No

**10.** <u>PUBLICATIONS / PRESENTATIONS</u>: (List any scientific publications and/or presentations that have resulted from this protocol. Include pending/scheduled publications or presentations).

None

### 11. Were the protocol objectives met, and how will the outcome or training benefit the DoD/USAF?

Yes. Residents became better prepared for entry knowledge of microvascular repair, but with the limited application in the clinical setting, I deem continuing the training is no longer relevant. If a microvascular surgeon returns to DGMC, than this will once again, be a valuable training exercise.

**12. PROTOCOL OUTCOME SUMMARY:** (Please provide, in "ABSTRACT" format, a summary of the protocol objectives, materials and methods, results - include tables/figures, and conclusions/applications.)

The purpose of this course is to familiarize PGY-3 Oral and Maxillofacial Surgery Residents with basic principles of microvascular surgery. At the conclusion of the course, the participant will be better suited to assist/perform basic techniques required in nerve and vessel reanastamosis. Over a 4 day period, the participant will learn via both didactic and hands-on experience. Using a rat model, the participant will learn to utilize basic microsurgical techniques and become familiar with the instrumentation. Hands on skill set will develop to further assist the resident in actual human patient procedures. The OMS microvascular course is an essential part of the contemporary Oral and Maxillofacial Surgery resident training. The course will provide the basic skills needed to perform and assist in human surgeries.

RYAN M. DIEPENBROCK. Lt Col. USAF. DC

8 Mar 2018\_\_ (Date)

#### Attachments:

Attachment 1: Defense Technical Information Center (DTIC) Abstract Submission

### Attachment 1 Defense Technical Information Center (DTIC) Abstract Submission

Objectives: The purpose of this course is to familiarize PGY-3 Oral and Maxillofacial Surgery Residents with basic principles of microvascular surgery. At the conclusion of the course, the participant will be better suited to assist/perform basic techniques required in nerve and vessel reanastamosis.

Methods: Over a 4 day period, the participant will learn via both didactic and hands-on experience. Using a rat model, the participant will learn to utilize basic microsurgical techniques and become familiar with the instrumentation.

Results: Hands on skill set will develop to further assist the resident in actual human patient procedures.

Conclusion: The OMS microvascular course is an essential part of the contemporary Oral and Maxillofacial Surgery resident training. The course will provide the basic skills needed to perform and assist in human surgeries.

At this point, I am suspending the course due to a lack of clinical application at DGMC

<b>Grant Num</b>	nber:
From:	
**If you uti	lized an external grant, please provide Grant # and where the grant came from. Thank you

<sup>&#</sup>x27;If you utilized an external grant, please provide Grant # and where the grant came from. Thank you.